End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.16 USD | -2.72% | 0.00% | -15.27% |
Jun. 03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
May. 30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
Financials (USD)
Sales 2024 * | 28.88M | Sales 2025 * | 43.41M | Capitalization | 177M |
---|---|---|---|---|---|
Net income 2024 * | -46M | Net income 2025 * | -44M | EV / Sales 2024 * | 6.12 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.07 x |
P/E ratio 2024 * |
-3.65
x | P/E ratio 2025 * |
-4.99
x | Employees | 101 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.5% |
Latest transcript on TriSalus Life Sciences, Inc.
1 day | -2.72% | ||
1 month | -26.26% | ||
3 months | -25.65% | ||
6 months | +80.35% | ||
Current year | -15.27% |
Managers | Title | Age | Since |
---|---|---|---|
Mary Szela
CEO | Chief Executive Officer | 60 | 17-12-31 |
Sean Murphy
DFI | Director of Finance/CFO | 71 | 23-08-09 |
Steven Katz
CTO | Chief Tech/Sci/R&D Officer | 49 | 23-08-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kerry Hicks
BRD | Director/Board Member | 64 | 23-08-09 |
Mats Wahlström
CHM | Chairman | 70 | 23-08-09 |
George Martin
BRD | Director/Board Member | 65 | 23-08-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 6.51 | -5.92% | 47,431 |
24-06-06 | 6.92 | -3.35% | 61,663 |
24-06-05 | 7.16 | -2.72% | 18,636 |
24-06-04 | 7.36 | -1.74% | 36,479 |
24-06-03 | 7.49 | +4.61% | 24,845 |
End-of-day quote Nasdaq, June 04, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.27% | 177M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- TLSI Stock